In Vivo Spatiotemporal Protection and Recognition of Circulating Tumor DNA for Early Cancer Diagnosis and Monitoring
New liposome-antibody strategy stabilizes tumor DNA in blood, enabling earlier and simpler cancer detection in animal studies.
This JACS study describes a novel in vivo strategy using liposomes and antibodies to protect circulating tumor DNA (ctDNA) from clearance, dramatically boosting its detectable levels in blood. The system enabled noninvasive tumor detection down to 30 mm³ and quantitative monitoring of treatment response in preclinical animal models.
What the study was
- Study design
- Preclinical/proof-of-concept in vivo animal model
- Population
- Tumor-bearing mouse models
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of the American Chemical Society
Why it surfaced
Highly novel in vivo ctDNA protection approach with impressive sensitivity metrics; preclinical-only status (animal model) caps score to 7 per scoring rules despite early detection flag.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.